Boston Scientific Corporation Stock
Equities
BSX
US1011371077
Advanced Medical Equipment & Technology
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
75.61 USD | +0.81% | -0.03% | +30.79% |
Sales 2024 * | 16B 21.8B | Sales 2025 * | 17.59B 23.97B | Capitalization | 111B 151B |
---|---|---|---|---|---|
Net income 2024 * | 2.2B 3B | Net income 2025 * | 2.73B 3.72B | EV / Sales 2024 * | 7.35 x |
Net Debt 2024 * | 6.42B 8.75B | Net Debt 2025 * | 3.62B 4.94B | EV / Sales 2025 * | 6.52 x |
P/E ratio 2024 * |
51.4
x | P/E ratio 2025 * |
41.7
x | Employees | 48,000 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 84.65% |
Latest transcript on Boston Scientific Corporation
1 day | +0.81% | ||
1 week | -0.03% | ||
Current month | +0.05% | ||
1 month | +4.71% | ||
3 months | +12.63% | ||
6 months | +34.68% | ||
Current year | +30.79% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Mahoney
CEO | Chief Executive Officer | 59 | 11-10-16 |
Daniel Brennan
DFI | Director of Finance/CFO | 58 | 96-11-30 |
Kenneth Stein
CTO | Chief Tech/Sci/R&D Officer | - | 09-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 71 | 16-07-12 | |
David Wichmann
BRD | Director/Board Member | 61 | 21-06-22 |
Director/Board Member | 69 | 15-03-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
2.26% | 12 M€ | +15.09% | - | |
1.98% | 1 M€ | +2.21% | - | |
1.75% | 17 M€ | +6.09% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 75.57 | +0.76% | 8,825,296 |
24-05-30 | 75 | +0.03% | 5,150,739 |
24-05-29 | 74.98 | -0.25% | 6,809,504 |
24-05-28 | 75.17 | -0.61% | 4,252,437 |
Delayed Quote Nyse, May 31, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+30.79% | 111B | |
+7.01% | 217B | |
+11.01% | 190B | |
+19.20% | 143B | |
+1.48% | 64.59B | |
+13.95% | 52.36B | |
-0.16% | 48.45B | |
-6.20% | 38.03B | |
+0.91% | 35.6B | |
+19.95% | 30.31B |
- Stock Market
- Equities
- BSX Stock